Generation Bio

GENERATION BIO CO

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Biotech

Earnings

Earnings Misses

News

Penny Stocks

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

GBIO

HOOK

Generation Bio Co. (NASDAQ: GBIO) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.47 per share a year ago. These figures are adjusted for non-recurring items.

Generation Bio Co. Reports Q2 Loss, Tops Revenue Estimates

Intraday Update

Movers

AAOI

ADPT

Advanced Environmental Recycling Technologies

AERT

AFRM

APVO

BIOL

BLNK

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

COMM

CREV

CUTR

CWCO

DOCS

DRCT

Sunrise New Energy Co., Ltd - Ordinary Shares

EPOW

FBIO

GCTK

GDOT

GRPN

ILMN

Intelligent Bio Solutions Inc. - Common Stock

INBS

INDV

INVO

IPDN

JYNT

LILA

LOCL

LYEL

MNTK

MRAI

MTEM

MVST

NMRD

OUST

PGEN

PLUG

PRPL

RCEL

RILY

SHCO

SNCR

SPRY

SYNA

TARS

TCON

TKLF

TMCI

TSHA

TWOU

VIRI

VUZI

VZIO

WEST

WHLR

WYNN

Shares of Wynn Resorts, Limited (NASDAQ: WYNN) fell sharply on Friday after the company reported third-quarter financial results.

Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Pre-Market Outlook

MRIN

Shares of  Direct Digital Holdings, Inc. (NASDAQ: DRCT) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results.

Why Direct Digital Shares Are Trading Higher By Around 33%; Here Are 20 Stocks Moving Premarket

Generation Bio Co

Press Releases

Generation Bio Reports Second Quarter 2024 Financial Results

Generation Bio to Present at the 2024 Cantor Global Healthcare Conference

Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress

Generation Bio Reports Recent Business Highlights and Third Quarter 2024 Financial Results

Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases

Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.

Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference

Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference

Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results

ABVC BioPharma

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

BioAtla

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

Clene

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dyadic International, Inc. - Common Stock

Dyadic International

FibroGen

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

MiNK Therapeutics

Kala Bio

Kezar Life Sciences

Lisata Therapeutics

Nanoviricides

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

OSR Holdings

Q32 Bio

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Tenax Therapeutics

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Vor Biopharma

Needham

Canaccord Genuity

Wedbush

JP Morgan

Comments

Generation Bio

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell